• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Infectious Disease

Interleukin-6 receptor antagonist treatment improves outcomes in COVID-19 patients

byAvneesh BhanguandHarsh Shah
March 3, 2021
in Infectious Disease, Public Health
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Treatment with tocilizumab and sarilumab increased the number of days without respiratory or cardiovascular organ support in patients with COVID-19.

2. Interleukin-6 receptor antagonists improved in-hospital survival for patients diagnosed with COVID-19 and receiving organ support in the ICU.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Thus far, only glucocorticoids have shown to improve survival in critically ill coronavirus disease 2019 (COVID-19) patients. Tocilizumab and sarilumab are monoclonal antibodies against receptors of interleukin-6 (IL-6), a key molecule in the acute-phase inflammatory response. This trial investigated the effectiveness of tocilizumab and sarilumab on organ support and survival in critically ill patients with COVID-19. Treatment with tocilizumab and sarilumab was found to improve the number of days critically ill patients in the ICU went without organ support. Furthermore, IL-6 receptor antagonist treatment improved 90-day survival in the same patient group compared to the control group. The study was not without limitations such as the lack of reporting on long-term outcomes and small sample size in the sarilumab group. This study’s results are significant, and its pragmatic, international design suggests results from this study may be generalized to use Il-6 receptor antagonist treatment in critically ill COVID-19 patients; however, caution must be taken as the standard of care may differ in other ICU’s.

Click to read the study in NEJM

Relevant Reading: Sarilumab use in severe SARS-CoV-2 pneumonia

In-Depth [randomized controlled trial]: Theis randomized control trial randomized 895 patients at 113 sites across six countries. Critically ill patients admitted to the ICU on organ support and ≥ 18 years of age were included. Patients previously participated in another study within 90 days or a presumption of imminent death were excluded from the study. The patients were randomized to one of five interventions – tocilizumab, sarilumab, anakinra (IL-1 receptor antagonist), interferon beta-1a, and control. The primary outcome was number of respiratory and cardiovascular organ support-free days up to day 21. The median number of organ support-free days for treatment modalities were 10 days with tocilizumab treatment (interquartile range, -1 to 16); 11 days with sarilumab treatment (interquartile range, 0 to 16); and 0 days in the control group 0 (interquartile range, -1 to 15). The median adjusted odds ratios for organ support-free days were 1.64 for tocilizumab treatment (95% confidence interval [CI] interval, 1.25-2.14) and 1.76 for sarilumab treatment (95% CI, 1.17-2.91). The in-hospital mortality for IL-6 receptor antagonist groups was 27% (108 of 395 patients) compared to 36% (142 of 397) patients in the control group. The median adjusted odds ratios for in-hospital survival were 1.64 in the tocilizumab treatment (95% CI, 1.14-2.35) and 2.01 in the sarilumab treatment (95% CI interval, 1.18-4.71). Therefore, IL-6 receptor antagonist therapy in critically ill ICU patients with COVID-19 was shown to improve outcomes, including survival.

RELATED REPORTS

#VisualAbstract: Tocilizumab may improve survival in COVID-19 patients with hypoxia and systemic inflammation

Tocilizumab may improve survival in COVID-19 patients with hypoxia and systemic inflammation 

#VisualAbstract: Tocilizumab reduced COVID-19 disease related adverse health outcomes

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: interleukin-6 receptor antagonistsarilumabTocilizumab
Previous Post

Prescription Opioid Misuse and Suicide Risk Behaviors Among High School Students

Next Post

Amoxicillin–clavulanate safer for patients with uncomplicated diverticulitis

RelatedReports

#VisualAbstract: Rifapentine-moxifloxacin noninferior to standard of care treatment for pulmonary tuberculosis
StudyGraphics

#VisualAbstract: Tocilizumab may improve survival in COVID-19 patients with hypoxia and systemic inflammation

May 19, 2021
Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children
Emergency

Tocilizumab may improve survival in COVID-19 patients with hypoxia and systemic inflammation 

June 25, 2021
#VisualAbstract: Tocilizumab reduced COVID-19 disease related adverse health outcomes
StudyGraphics

#VisualAbstract: Tocilizumab reduced COVID-19 disease related adverse health outcomes

March 10, 2021
Prescription of antibiotics for acute respiratory infections increasing
Infectious Disease

Tocilizumab reduced COVID-19 disease related adverse health outcomes

March 4, 2021
Next Post
Quick Take: Long-term outcome of surgery versus conservative management for recurrent and ongoing complaints after an episode of diverticulitis

Amoxicillin–clavulanate safer for patients with uncomplicated diverticulitis

#VisualAbstract: Aromatase inhibitors superior to tamoxifen for  progression-free survival in HR⁺ advanced breast cancer

#VisualAbstract: Aromatase inhibitors superior to tamoxifen for progression-free survival in HR⁺ advanced breast cancer

Influenza vaccine not associated with increased risk of epilepsy in children

Heterologous recombinant adenovirus-based COVID-19 vaccine (Gam-COVID-Vac) is tolerable and highly efficacious

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Stereotactic body radiotherapy as a state of the art treatment option in inoperable non-small cell lung cancer [Classics Series]
  • Health system-based care associated with better treatment use and high rates of tobacco abstinence at 3 months post-discharge in hospitalized smokers
  • APOEε4 genotype may increase risk of chronic traumatic encephalopathy following repetitive head impact
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.